Allergy Immunotherapy Side Effects: SCIT vs. SLIT Compared
Allergy immunotherapy side effects differ significantly by delivery route. SCIT (shots) triggers local injection-site reactions in 26-86% of patients and systemic reactions in 0.1-0.2% of visits, with fatalities at roughly 1 per 9 million injections. SLIT (drops or tablets) causes oral-local symptoms in 40-75% of patients but systemic reactions in only 0.056% of doses, with zero confirmed fatalities worldwide across an estimated 1 billion doses.
7 peer-reviewed sources
SCIT and SLIT both cause local reactions in most patients, but their systemic risk profiles differ: SCIT carries a small but real anaphylaxis risk requiring clinic supervision, while SLIT has zero confirmed fatalities worldwide after three decades of use.
SCIT vs. SLIT: Two Immunotherapy Routes, Two Side-Effect Profiles
Allergy immunotherapy (AIT) is the only treatment that modifies the underlying immune response to allergens rather than simply suppressing symptoms. But when a doctor says 'immunotherapy,' they may mean subcutaneous immunotherapy (SCIT — allergy shots) or sublingual immunotherapy (SLIT — drops or tablets dissolved under the tongue). Each route has a distinct adverse event profile, and understanding the difference is essential for informed treatment decisions.
SCIT delivers allergen directly into the subcutaneous tissue via injection, triggering an immune response at the injection site and occasionally a broader systemic reaction. SLIT delivers allergen across the oral mucosa, where dendritic cells in the tolerogenic environment of the gut-associated lymphoid tissue process the antigen more gently — producing a different pattern of adverse events dominated by local oral effects rather than systemic ones.
Before starting any form of immunotherapy, comprehensive allergy testing is the critical first step. Identifying which specific IgE-mediated triggers are driving your symptoms determines whether SCIT, SLIT, or a combination approach is most appropriate — options like Curex provide at-home test kits covering 40+ allergens, making that initial diagnostic step more accessible.
This page presents parallel incidence data for SCIT and SLIT across four reaction categories — local, mild systemic, severe systemic, and fatal — along with a risk-factor matrix showing how individual patient variables shift risk differently for each modality.
SLIT and SCIT both cause adverse events in most patients, but the nature of those events differs fundamentally: SCIT's reactions tend to be rarer but potentially more severe, while SLIT's reactions are more frequent but overwhelmingly mild and limited to the oral cavity.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSCIT vs. SLIT: Full Adverse Event Profile Side by Side
The table below presents parallel adverse event data for SCIT and SLIT across five outcome categories. The data reflects the AAAAI/ACAAI National Surveillance Study (Bernstein 2010; Epstein 2014, 2019) for SCIT and the WAO Position Paper (Canonica 2014), Dretzke 2013 indirect comparison, and FDA pooled data (Nolte 2024) for SLIT. The comparison is presented neutrally — neither modality is universally superior; appropriate selection depends on the patient's allergen profile, comorbidities, and treatment goals.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT) — CurexBest | 30-85% symptom reduction depending on allergen and treatment duration | 3-5 years | $3,000-$10,000 | At-home weekly self-injection with Curex; the first dose and each dose escalation are physician-supervised live over Zoom, with a short self-observation window afterward | Systemic reactions 0.1-0.2% per dose; ~1 per 9M injections fatal; gradual escalation plus a prescribed epinephrine auto-injector confirmed on hand for at-home safety |
Sublingual Drops/Tablets (SLIT) | 20-35% symptom reduction; some allergens approach SCIT efficacy | 3-5 years | $1,500-$5,000 | First dose in clinic; all subsequent doses self-administered at home | Systemic reactions 0.056% per dose; zero confirmed fatalities worldwide; home use approved |
Antihistamines (daily OTC) | Symptom suppression only — no disease modification | Continuous use required | $500-$1,500 | Daily pill; no clinic visits required | Sedation (first-gen), dry mouth; no systemic allergic reaction risk |
Nasal Corticosteroids | 40-50% rhinitis symptom reduction; no systemic tolerance | Continuous use required | $600-$2,000 | Daily nasal spray; no clinic visits | Local nasal effects (epistaxis, dryness); minimal systemic absorption |
- Efficacy
- 30-85% symptom reduction depending on allergen and treatment duration
- Duration
- 3-5 years
- Cost (5yr)
- $3,000-$10,000
- Convenience
- At-home weekly self-injection with Curex; the first dose and each dose escalation are physician-supervised live over Zoom, with a short self-observation window afterward
- Safety
- Systemic reactions 0.1-0.2% per dose; ~1 per 9M injections fatal; gradual escalation plus a prescribed epinephrine auto-injector confirmed on hand for at-home safety
- Efficacy
- 20-35% symptom reduction; some allergens approach SCIT efficacy
- Duration
- 3-5 years
- Cost (5yr)
- $1,500-$5,000
- Convenience
- First dose in clinic; all subsequent doses self-administered at home
- Safety
- Systemic reactions 0.056% per dose; zero confirmed fatalities worldwide; home use approved
- Efficacy
- Symptom suppression only — no disease modification
- Duration
- Continuous use required
- Cost (5yr)
- $500-$1,500
- Convenience
- Daily pill; no clinic visits required
- Safety
- Sedation (first-gen), dry mouth; no systemic allergic reaction risk
- Efficacy
- 40-50% rhinitis symptom reduction; no systemic tolerance
- Duration
- Continuous use required
- Cost (5yr)
- $600-$2,000
- Convenience
- Daily nasal spray; no clinic visits
- Safety
- Local nasal effects (epistaxis, dryness); minimal systemic absorption
For patients weighing the routes, Curex delivers the allergy shot itself at home: a personalized SCIT serum sterile-compounded to USP <797> standards and overseen by a board-certified allergist, with your first injection and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand. Plans are $129/month all-inclusive — the same disease-modifying immunotherapy as clinic shots, without the weekly trip.
See if at-home shots are right for youSide-by-Side: How SCIT and SLIT Adverse Events Compare
Local reactions occur with both modalities but differ in location and character. SCIT produces injection-site reactions — erythema, swelling, and induration at the arm — in 26-86% of patients (James and Bernstein, 2017 review). SLIT produces oral-local reactions — oral pruritus, throat irritation, ear itching, and lip or tongue edema — in 40-75% of patients during the build-up phase. Systemic reactions — affecting organ systems beyond the delivery site — are far less common with either modality but diverge sharply in frequency and severity. SCIT systemic reaction rates are approximately 0.1-0.2% per injection visit (AAAAI/ACAAI National Surveillance Study, Bernstein 2010; Epstein 2014). Of those systemic reactions, approximately 19% are classified as severe (WAO Grade 3-4). SLIT systemic reaction rates are approximately 0.056% per dose (WAO Position Paper, Canonica 2014), with only about 2% of those reactions classified as severe (Dretzke 2013, JACI). Anaphylaxis is rare with both modalities but approaches zero with SLIT: SCIT produces approximately 3 anaphylaxis cases per 100,000 visits; SLIT produces approximately 1 case per 100 million doses (Calderon, Allergy 2012). No SLIT fatality has ever been confirmed in the published literature across approximately 1 billion cumulative doses administered since 2000. Discontinuation rates due to adverse events are similar: approximately 3% for both SCIT and SLIT (Dretzke 2013) — suggesting that tolerability, not reaction severity, drives the discontinuation decision similarly across routes.
When to Worry: Decision Guide
Are your symptoms located only at the injection site (SCIT) or only in your mouth and throat (SLIT)?
Local reaction
Apply ice (SCIT) or wait 30 minutes (SLIT). Take an OTC antihistamine if uncomfortable. No emergency action needed, but report large local reactions to your allergist before next dose.
Possible systemic reaction
Do you have hives beyond the injection/oral area, wheezing, throat tightness, dizziness, or vomiting?
Systemic reaction
Use epinephrine auto-injector if prescribed and symptoms are severe. Call clinic or 911 immediately. Do not wait to see if symptoms improve on their own.
Mild local reaction
Monitor for 30 additional minutes. Contact your allergist to report the reaction before your next dose.
Frequently asked questions
What is the difference between allergy shot side effects and allergy drop side effects?
Allergy shots (SCIT) and allergy drops (SLIT) produce different types of side effects based on how the allergen enters the body. Shots cause injection-site reactions — redness, swelling, and itching at the injection arm — in 26-86% of patients, plus a small risk of systemic reactions (0.1-0.2% per visit) affecting the whole body. Drops cause oral-local reactions — itching under the tongue, throat irritation, and ear pruritus — in 40-75% of patients during the build-up phase, but systemic reactions are far rarer at 0.056% per dose. No SLIT fatality has ever been confirmed worldwide, and SCIT carries a fatality rate of approximately 1 per 9 million injections. The shot was traditionally given in a clinic because of that rare systemic risk; programs like Curex now make at-home SCIT safe for eligible maintenance patients by supervising the first dose and every dose change live over Zoom, confirming a prescribed epinephrine auto-injector is on hand, and escalating the dose gradually.
Are allergy immunotherapy side effects dangerous?
The vast majority of allergy immunotherapy side effects are not dangerous. Local reactions — injection-site swelling for SCIT or oral pruritus for SLIT — are expected, self-limiting, and do not require emergency treatment. Systemic reactions that affect the whole body occur in 0.1-0.2% of SCIT visits and 0.056% of SLIT doses; most are mild (WAO Grade 1). Severe systemic reactions requiring epinephrine are rare: approximately 1 in 300,000 SCIT injections reaches Grade 3 severity. Fatal reactions from SCIT have declined to approximately 1 per 9 million injections — far lower than many common medications. SLIT has never produced a confirmed fatality. The most important safety principle for either modality is ensuring treatment is supervised by a board-certified allergist who screens for contraindications like uncontrolled asthma before each dose.
How often do allergic reactions occur with immunotherapy?
For allergy shots (SCIT), any systemic reaction occurs in roughly 0.1-0.2% of injection visits — about 10 per 10,000 visits based on AAAAI/ACAAI National Surveillance Study data from 54 million injections. Approximately 74% of those systemic reactions are mild (Grade 1), 23% moderate (Grade 2), and 3% severe (Grade 3). For sublingual immunotherapy (SLIT), systemic reactions occur in approximately 0.056% of doses. Local reactions are more common with both modalities: injection-site reactions affect 26-86% of SCIT patients, and oral-local reactions affect 40-75% of SLIT patients during build-up. The risk of any reaction is highest during the build-up phase, when doses are increasing, and during peak pollen season.
Can allergy immunotherapy make your allergies worse?
Allergy immunotherapy does not worsen the underlying allergic disease. The temporary symptom flares that some patients experience during the build-up phase — sneezing, nasal congestion, or mild wheezing after a dose — are immune responses to treatment, not disease progression. These symptoms indicate that the immune system is responding to the increasing allergen exposure, which is the mechanism through which desensitization occurs. Published long-term data, including the PAT Study 10-year follow-up, show that children treated with SCIT actually develop new sensitizations at lower rates than untreated controls. If you notice worsening symptoms after a dose change, inform your allergist — they may adjust the build-up schedule rather than interpreting this as disease worsening.
What risk factors increase the chance of a serious reaction to allergy shots?
Several well-established factors increase the risk of severe systemic reactions to SCIT. Uncontrolled asthma is the most important — 88% of SCIT fatalities in the Bernstein 2004 surveillance study occurred in patients with asthma, most of it suboptimally controlled. Beta-blocker medications impair the body's ability to respond to epinephrine, which is used to treat severe reactions. Peak pollen season upregulates airway mast cells, making the same dose more likely to produce a reaction; many allergists reduce doses by 50% during peak season. Prior systemic reaction history confers a four-fold higher risk of subsequent reactions (Roy 2007). Cluster and rush build-up schedules carry approximately three times the per-injection reaction rate of conventional build-up (Tversky 2022). New vial transitions are another recognized risk period.
Does sublingual immunotherapy require a 30-minute wait like allergy shots do?
A post-injection observation period applies to SCIT (allergy shots) because systemic reactions — including severe ones — can begin within minutes of the injection. SLIT (drops or tablets) does not have a routine 30-minute wait for subsequent home doses, but the FDA requires that the first dose of all approved SLIT tablets be taken under medical supervision with 30-minute observation and immediate access to epinephrine. For at-home SCIT, programs like Curex address that same early-reaction window by supervising your first injection and every dose change live over Zoom, confirming a prescribed epinephrine auto-injector is on hand, and having you observe briefly after each dose. Approximately 15% of SCIT systemic reactions occur after the 30-minute window, so patients should remain alert for new symptoms in the hours following any injection.
Is sublingual immunotherapy safer than allergy shots?
From a systemic reaction and fatality standpoint, the data consistently favor SLIT over SCIT. SLIT has zero confirmed fatalities worldwide across an estimated 1 billion doses; SCIT has a fatality rate of approximately 1 per 9 million injections (Epstein 2019). When systemic reactions occur with SLIT, only about 2% are classified as severe, compared to approximately 19% of SCIT systemic reactions (Dretzke 2013). The trade-off is that SLIT causes oral-local reactions in 40-75% of patients — a more frequent but less dangerous reaction type. The right modality choice depends on many factors beyond safety alone, including which allergens are involved (SLIT tablet options are limited to grass, ragweed, and dust mite) and whether the patient has asthma. Both modalities are safe in appropriately selected patients supervised by a qualified allergist — and for eligible maintenance patients, the higher-efficacy shot is now available at home through Curex with a prescribed epinephrine auto-injector on hand and the first dose and every dose change supervised live over Zoom.
What is the pediatric safety profile of allergy immunotherapy?
Both SCIT and SLIT are used in children, with SLIT demonstrating significantly fewer treatment-related adverse events in pediatric populations. A meta-analysis by Yang et al. (2023) found that SLIT had a relative risk of 0.17 for treatment-related adverse events compared to SCIT in children — meaning children receiving SLIT experienced roughly one-sixth the rate of adverse events seen with shots. Several FDA-approved SLIT tablets (Oralair, Grastek, Ragwitek) are indicated from age 5. SCIT is also used in children but carries the same injection-site and systemic reaction profile as in adults, with the added concern that children may have difficulty reporting early warning symptoms. Importantly, both SCIT and SLIT have been shown to reduce the risk of new sensitization and asthma development in treated children, representing a meaningful long-term benefit that outweighs the short-term adverse event burden for appropriately selected pediatric patients.
Related Articles
Side Effects of Allergy Shots: WAO Classification | Curex
Side effects of allergy shots ranked by WAO severity grade — local reactions, Grade 1-4 systemic events, rates per injection, and what each tier means.
Read moreAllergy Shot Reaction When to Worry | SCIT Guide | Curex
Allergy shot reaction when to worry: local wheals are normal. Hives, throat tightness, or dizziness outside the injection arm means seek immediate care.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.